Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价四价流感病毒裂解疫苗姐终于3周岁及以上健康人群的免疫原性和安全性的随机双盲、阳性对照的III期临床试验
[Translation] A randomized, double-blind, positive-controlled Phase III clinical trial to evaluate the immunogenicity and safety of the quadrivalent influenza virus split vaccine in healthy people aged 3 years and above.
证明3周岁及以上受试者全人群接种1剂试验用疫苗后30天的免疫原性和安全性
[Translation] Prove the immunogenicity and safety of the entire population of subjects aged 3 years and above 30 days after receiving one dose of the experimental vaccine
评价水痘减毒活疫苗接种不同年龄健康人群安全性的随机、盲法、阳性对照的Ⅰ期临床试验
[Translation] A randomized, blinded, positive-controlled phase I clinical trial to evaluate the safety of live attenuated varicella vaccine in healthy people of different ages.
评价1周岁及以上健康人群接种水痘减毒活疫苗的安全性。
[Translation] To evaluate the safety of live attenuated varicella vaccine in healthy people aged 1 year and above.
100 Clinical Results associated with Chengda Biology (Benxi) Co., Ltd.
0 Patents (Medical) associated with Chengda Biology (Benxi) Co., Ltd.
100 Deals associated with Chengda Biology (Benxi) Co., Ltd.
100 Translational Medicine associated with Chengda Biology (Benxi) Co., Ltd.